Suppr超能文献

初探明日诊断技术:《分子诊断学专家评论》创刊 15 周年总编观点。

Scratching the surface of tomorrow's diagnostics: the Editor-in-Chief's opinion at the 15th year of Expert Review of Molecular Diagnostics.

机构信息

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, EC1M 6BQ, UK.

出版信息

Expert Rev Mol Diagn. 2015 Jan;15(1):5-8. doi: 10.1586/14737159.2015.998959.

Abstract

Interview with Attila Lorincz by Claire Raison (Commissioning Editor) To mark the beginning of the 15th year of Expert Review of Molecular Diagnostics, the journal's Editor-in-Chief shares his expert knowledge on translational diagnostics, his opinion on recent controversies and his predictions for molecular diagnostics in 2015 and beyond. Attila Lorincz received his doctorate from Trinity College, Dublin, Republic of Ireland, and went on to become a research fellow at the University of California, Santa Barbara, CA, USA. During Professor Lorincz's research on human papillomavirus (HPV), he found several important and novel carcinogenic HPV types and pioneered the use of HPV DNA testing for clinical diagnostics. In 1988, Professor Lorincz's team produced the first HPV test to be FDA-approved for patients and in 2003, for general population cervical precancer screening. Now Professor of Molecular Epidemiology at the Centre for Cancer Prevention, Queen Mary University of London, UK, he and his team are furthering translational research into DNA methylation assays for cancer risk prediction.

摘要

采访阿提拉·洛林茨(Attila Lorincz)博士 克莱尔·雷森(Claire Raison)(委托编辑) 为庆祝《分子诊断学专家评论》创刊 15 周年,该杂志的主编分享了他在转化诊断方面的专业知识,对最近的争议发表了看法,并对 2015 年及以后的分子诊断学进行了预测。阿提拉·洛林茨博士毕业于爱尔兰都柏林三一学院,随后成为美国加利福尼亚大学圣巴巴拉分校的研究员。在研究人类乳头瘤病毒(HPV)期间,洛林茨教授发现了几种重要且新颖的致癌 HPV 类型,并率先将 HPV DNA 检测用于临床诊断。1988 年,洛林茨教授的团队生产了第一个获得 FDA 批准用于患者的 HPV 检测方法,并于 2003 年用于普通人群的宫颈癌前病变筛查。现任英国伦敦玛丽女王大学癌症预防中心分子流行病学教授,他和他的团队正在进一步开展 DNA 甲基化检测用于癌症风险预测的转化研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验